DoMore Diagnostics vs Valar Labs (2026)
Both predict how a cancer will behave from routine H&E slides, in different cancers and markets. DoMore's Histotype Px Colorectal is CE-IVDD marked for stage II and III colorectal cancer, validated in the QUASAR 2 trial cohort and run through Sectra, PathAI and Proscia platforms, with no FDA clearance. Valar's Vesta tests run in its own US CLIA laboratory for non muscle invasive bladder cancer, predicting BCG non response and recurrence and progression risk.
- Your patients have stage II or III colorectal cancer and adjuvant chemotherapy is the decision.
- You work in Europe, where the test is CE-IVDD marked.
- You want to run the test inside Sectra's Amplifier Marketplace, PathAI's AISight or Proscia's Concentriq Dx.
- Your patients have non muscle invasive bladder cancer and BCG response is the question.
- You want a US laboratory service rather than software you run.
- You want evidence from multicenter bladder studies in the Journal of Urology and European Urology.
This comparison is published by AI Health Index, an independent research platform that compares healthcare AI vendors objectively. DoMore Diagnostics and Valar Labs are each graded against the same capability taxonomy, from each vendor's own public materials and the regulatory record, under the AI Health Index verification standard. No vendor pays for placement, and no vendor has reviewed this page. How this evidence is graded
Plain facts
| Fact | DoMore Diagnostics | Valar Labs |
|---|---|---|
| Primary category | Digital Pathology AI | Digital Pathology AI |
| Founded | 2020 | 2021 |
| Headquarters | Oslo, Norway | Palo Alto, California, United States |
| Website | domorediagnostics.com | valarlabs.com |
Side by Side
Select any grade to read the note behind it.
Product updates
The latest logged changes from each vendor, newest first, each linked to its source.
Valar Labs
-
Model / architecture
Valar Labs described CHAI, the vision foundation model behind its tests, in the first of a four part series.
Source -
Clinical evidence
Valar Labs and clinical partners published a peer-reviewed study in Urologic Oncology detailing the development and validation of an image-only AI prognostic biomarker for muscle-invasive bladder cancer (MIBC).
Source
Each vendor in one paragraph
Written to be quoted whole. Each paragraph opens the AI Health Index profile of the vendor: what the product is, who buys it and what it does.
Oslo based company whose Histotype Px Colorectal predicts recurrence and survival in stage II and III colorectal cancer from standard H and E stained slides, placing patients in risk groups to inform whether adjuvant chemotherapy should follow surgery. The product page states CE-IVDD marking; there is no FDA clearance.
Source: AI Health Index, September 2026
Valar Labs is a precision oncology company, founded in 2021, whose tests predict treatment response and prognosis from routine H and E slides using its Computational Histology AI platform, trained on more than 500,000 pathologist annotations. The tests run in Valar's own CLIA certified laboratory and are ordered by physicians through a web portal, with results in two to three days.
Source: AI Health Index, September 2026
Questions buyers ask
How do DoMore Diagnostics and Valar Labs work with the EHR?
For DoMore Diagnostics, the products page says Histotype Px Colorectal is available on Sectra's Amplifier Marketplace, PathAI's AISight and Proscia's Concentriq Dx, and the partners page describes the Sectra and PathAI collaborations; PathAI's own algorithm menu lists the product.
The clinic submits basic patient information through Valar's secure online portal, Valar requests the specimen from pathology, and results come back in about two to three days for prostate and pancreas and about three days for bladder. A clinician quoted on the bladder page describes fitting it into the practice's workflow. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified September 28, 2026. No vendor pays for placement.
How are DoMore Diagnostics and Valar Labs priced and sold?
In DoMore Diagnostics' case, the company states that most stage II and III colorectal patients are cured by surgery alone and that adjuvant chemotherapy benefits few of them, so the value of Histotype Px is avoided chemotherapy and toxicity, and it presents the test as giving risk information soon after surgery.
Valar runs a Financial Access Program for patients with financial need. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified September 28, 2026. No vendor pays for placement.
How do DoMore Diagnostics and Valar Labs handle patient data?
With DoMore Diagnostics, the privacy policy covers personal data from website visits, email contact and job applications, with retention periods for those, and does not address slides or results from the product.
The Notice of Privacy Practices (effective 1 January 2025) lets Valar de-identify health information and use it for research with the protections the law requires, and requires written authorization for marketing and any sale. The website privacy policy (29 April 2024) says personal information may be used for research and development, including to create de-identified data. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified September 28, 2026. No vendor pays for placement.
Which settings and specialties do DoMore Diagnostics and Valar Labs cover?
For DoMore Diagnostics, the company says it was developed on 4,500 patient samples and 90 million image tiles, with slides prepared at several sites and scanned at two sites on two different scanners, and it was validated in the QUASAR 2 trial cohort (The Lancet Oncology). Clinical validation studies are running with Gustave Roussy, Erasmus MC (up to 2,200 rectal cancer patients), IFOM Milan and Ohio State.
With Valar Labs, all run on existing H and E slides. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified September 28, 2026. No vendor pays for placement.
Related comparisons
Other published head to head assessments involving these vendors or their closest peers. The full set for this category is on the Clinical Decision Support page.
Neither holds an FDA clearance; a Breakthrough Device Designation on a Valar test is a development status, not an authorization. Rewritten 28 Sep 2026 after both records were reviewed.